SS Innovations Stock Price, News & Analysis

SS Innovations (NASDAQ:SSII) has achieved a significant milestone by installing over 100 SSi Mantra surgical robotic systems across India and six other countries. The company reported that more than 5,000 surgical procedures have been completed using the system, including 240 cardiac surgeries and 32 telesurgeries, showing substantial growth from the 2,759 total procedures reported as of December 31, 2024.

The company plans to submit a De Novo application to the FDA by July 2025 for multiple indications and is pursuing European Union CE marking certification, expected by late 2025. SS Innovations aims to democratize robotic surgery access by expanding both in existing markets and new geographies.

SS Innovations (NASDAQ:SSII) has achieved a groundbreaking milestone by completing the world's first robotic telesurgery for weight loss using their SSi Mantra 3 surgical robotic system. The surgery was performed by Dr. Mohit Bhandari from a distance of 560 miles, connecting SS Innovations' headquarters in Gurugram to Mohak Bariatric & Robotic Surgery Centre in Indore, India.

Two One-Anastomosis Gastric Bypass (OAGB) procedures were successfully executed with zero perceptible lag and flawless precision. The achievement demonstrates the system's capability to deliver advanced surgical care to remote locations, potentially revolutionizing healthcare accessibility and affordability globally.

SS Innovations International (NASDAQ: SSII) announced the successful completion of the first robotic cardiac surgery in the Americas using their SSi Mantra 3 surgical robotic system. The groundbreaking procedure, an Atrial Septal Defect closure, was performed by Dr. Juan Zuniga at Interhospital in Guayaquil, Ecuador on June 8, 2025. The surgery involved repairing a hole between the heart's upper chambers. Dr. Zuniga praised the system's ease of use, precision, and effectiveness, noting faster patient recovery, minimal bleeding, and precise tissue manipulation. Interhospital, the first South American facility to install the SSi Mantra system, has been successfully using it for various complex surgical procedures.

SS Innovations International (NASDAQ: SSII), a surgical robotics technology company, will ring the Nasdaq opening bell on June 3, 2025, celebrating their April 2025 Nasdaq uplisting. The ceremony will be led by CEO Dr. Sudhir Srivastava and company leadership. The event also marks the milestone of over 4,000 successful robotic surgeries completed using their SSi Mantra system across more than 100 surgery types, with zero complications. The SSi Mantra, designed as a cost-effective surgical robotic system, has gained adoption in India and six other countries. The company is actively pursuing expansion into new markets, including the EU and US, with a mission to make advanced robotic surgery more accessible and affordable globally.

SS Innovations (NASDAQ: SSII) has achieved a significant milestone with its SSi Mantra surgical robotic system, successfully completing over 4,000 robotic surgeries across more than 100 types of procedures with zero complications. Notable achievements include 215 cardiac surgical procedures, with six performed via telesurgery across India using the SSi Mantra 3 system.

The system is currently approved in seven countries including India, Nepal, Ecuador, Guatemala, Philippines, Indonesia, and Ukraine. The company is pursuing market expansion with expected European Union CE Mark decision by late 2025 and FDA approval targeted for first half of 2026. The SSi Mantra system supports various surgical specialties including general surgery, urology, gynecology, cardiac, gastrointestinal, thoracic, head and neck, and breast and plastic procedures.

SS Innovations (NASDAQ: SSII) reported strong Q1 2025 financial results with record quarterly revenue of $5.1 million, up 40.8% year-over-year. The growth was driven by increased sales of their SSi Mantra 3 surgical robotic system. Key highlights include: - 15 new system installations (66.7% increase YoY) - Gross margin expanded to 21.23% - Net loss improved to $5.7 million ($0.03/share) vs $9.8 million ($0.06/share) in Q1 2024 - Cumulative installed base reached 78 units with 3,568 total surgeries performed - Cash position of $15.9 million with zero long-term debt The company achieved a significant milestone with its Nasdaq uplisting in April 2025 and plans to submit a De Novo FDA application for SSi Mantra 3 by July 2025, while pursuing EU CE Mark approval by late 2025.

SS Innovations International (NASDAQ: SSII) announced plans to submit a De Novo Classification Request to the FDA for its SSi Mantra 3 surgical robotic system in July 2025. The company has demonstrated significant market traction with 80 SSi Mantra systems installed across 75 hospitals since August 2022, facilitating over 3,800 surgeries. The newer SSi Mantra 3 version, launched in June 2024, has 37 installations and has been used in more than 750 procedures, including 70 cardiac cases, with no device-related complications.

The FDA submission will seek approval for multiple surgical specialties including urology, gynecology, general surgery, and thoracic and cardiac surgery. The system is currently approved in six countries, and the company is simultaneously pursuing EU CE Mark approval.

SS Innovations (NASDAQ: SSII) has reiterated its Q1 2025 guidance and provided Q2 2025 order trends. The company installed 14 SSi Mantra surgical robotic systems in Q1 2025, bringing the total installed base to 78 systems as of March 31, 2025. Expected Q1 2025 revenue is approximately $6.4 million with a 45% gross margin. As of April 30, 2025, the installed base reached 80 systems across 75 hospitals, with over 3,800 surgeries completed, including more than 200 robotic cardiac surgeries. System orders in April 2025 totaled 9 units, representing a 200% increase from April 2024. The company plans to report Q1 2025 financial results around May 15, 2025.

SS Innovations International (NASDAQ: SSII), a surgical robotics technology company, has announced a planned CFO transition. Arvind Palaniappan has been appointed as Interim CFO effective May 1, 2025, replacing Anup Sethi, who served as CFO during the company's growth phase. Under Sethi's seven-year tenure, the company successfully launched over 80 surgical robotic systems in India and internationally, and recently achieved a milestone with its Nasdaq uplisting on April 25. The company has initiated a search for a permanent CFO, while Sethi will remain available in an advisory capacity during the transition period.